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Abstract: Cancer is a worldwide burden resulting in millions of deaths each year. In particular,
gastrointestinal tumors are life-threatening malignancies and one of the leading reasons for death in
developed countries. Phytochemicals can be found in grains, vegetables, fruits and several foods.
Many phytochemicals, such as curcumin, genistein, luteolin, vitexin-2-O-xyloside, avenanthramides,
quercetin, epigallocatechin-3-gallate (EGCG), resveratrol, sulforaphane, piperine and thymoquinone
have been used in combination with different chemotherapeutic agents for their synergistic anticancer
effects against various forms of cancer. In this review, we describe the antitumor properties and
biological effects of combinations of phytochemicals and anticancer drugs against gastrointestinal
tumors: colon cancer, gastric cancer, liver cancer, pancreatic cancer. We focus on the molecular
pathways, oncoproteins and tumor suppressors modulated by the combination of phytochemicals
with antitumor drugs and on the biomarkers of the hallmarks of cancer influenced by these therapeu-
tic strategies in cancer cell lines, xenograft models and clinical trials. The increased knowledge of
biomarkers and molecular pathways regulated by the combination of phytochemicals and conven-
tional anticancer drugs in both in vitro and in vivo models will remarkably improve the efficacy of
these therapeutic strategies against gastrointestinal tumors in future innovative clinical applications.
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1. Introduction
Carcinogenesis is the process that characterizes the transformation of normal cells
into tumor cells [1]. This process is driven by the accumulation of genetic mutations and
the alteration of epigenetic regulatory mechanisms [1]. During metastasis development,
the spreading of primary tumor cells to distant tissues and organs takes place [2]; the
metastasis cascade consists of five steps: invasion; intravasation; systemic transportation;
extravasation and colonization of the new site [3]. Metastasis formation is linked to the
Epithelial to Mesenchymal Transition (EMT) process [4]. In the EMT multiple, distinct
cellular subpopulations are involved, including the cancer stem cells (CSCs), that can
regenerate the cells of the tumor core [5]. It has been demonstrated that the cells of the
core of tumor mass live in hypoxic conditions, resulting in activation of hypoxia inducible
factors (HIF-1α and HIF-2α), that are able to increase the expression of several genes, such
as vascular endothelial growth factor A (VEGFA), leading to events of neo-angiogenesis and
enhancement of vessel permeability [6]. In particular, HIF-1α is an essential protein for EMT
activation and metastasis development [7]. Importantly, there are two kinds of antitumor
drugs used against tumors characterized by metastasis development: anti-angiogenic and
anti-metastatic synthetic molecules; these drugs target specific characteristics of tumor
cells, called hallmarks of cancer [8]. The hallmarks of cancer include: increased signaling
for proliferation, evading growth inhibitors, evading apoptosis, replicative immortality,
increased angiogenesis, activated invasion and metastasis development, genome mutations,
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pro-inflammatory conditions, altered energy metabolism and evading immune destruction,
to which the tumor micro-environment contributes [1]. Furthermore, another hallmark
plays a pivotal role in cancer development: the multidrug resistance (MDR) of cancer cells,
acquired through overexpression of MDR genes and increased levels of P-glycoprotein
(P-gp), which is involved in the efflux of chemotherapeutic drugs from tumor cells [9].
Conventional anticancer drugs specifically target over-proliferating tumor cells; im-
portantly, new therapeutic strategies have been developed, focused on a combination of
chemotherapeutic agents and chemoprevention [10]. The role of diet in tumor chemo-
prevention has been indicated by many authors, who described the relationship between
phytochemicals present in food and their antitumor properties [11–13]. Apoptosis is the
main mechanism through which phytochemicals induce the death of tumor cells, after
the activation of specific enzymes called caspases [14]. Three apoptotic pathways have
been described: the extrinsic pathway, where caspase 8, caspase 3 and the multi-protein
complex Fas-associated protein with death domain (FADD)osome (Figure 1) play a piv-
otal role [1], endoplasmic reticulum pathway [15] and the intrinsic pathway [1], where
caspases 2, 9 and 3 are involved [16,17]. As regards caspase 2, this enzyme is activated by
reactive oxygen species (ROS). The role of ROS, increased DNA damage and multi-protein
complex p53-induced death domain containing protein (PIDD)osome (Figure 1) in the
maturation and activation of caspase 2 has been described [16]. Noteworthy, inhibitor of
apoptosis proteins (IAPs) are able to suppress the intrinsic pathway of apoptosis, in partic-
ular through an increase of Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5)
expression levels and survivin protein levels [18]. This IAP can inhibit the caspase 9 activity,
blocking the formation of the apoptosome (Figure 1) [18].
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Figure 1. Graphical representations of (A) apoptosome, (B) FADDosome, (C) PIDDosome. TRAIL:
TNF-related apoptosis inducing ligand, DR5: Death Receptor 5, RAIDD: RIP-associated ICH1/CED3-
homologous protein with a death domain.
Several phytochemicals and synthetic molecules derived from natural compounds
can activate the intrinsic or the extrinsic apoptotic pathways [19–22]. Interestingly, it has
been shown that a phytochemical combination of moringin (MOR) and avenanthramide 2f
was able to induce the activation of caspases 8,9,2 and 3 in the hepatocarcinoma Hep3B
cells, leading to a significant decrease of their proliferation rate [23]. Importantly, several
plant phytochemicals possess both antiproliferative and proteasome-inhibitory activity, in-
cluding epigallocatechin-3-gallate (EGCG), genistein, luteolin, apigenin, chrysin, quercetin,
curcumin and tannic acid. These polyphenols have exhibited an appreciable effect on
overcoming resistance to various chemotherapeutic drugs as well as multidrug resistance
in a broad spectrum of tumors ranging from carcinomas and sarcomas to hematological
malignancies [24].
Eukaryotic proteasome 26S consists of the 20S core and two 19S caps [25]. Interestingly,
proteasome activity can modulate the levels of B-cell leukemia/lymphoma 2 (Bcl-2) family
proteins, Nuclear factor-kappa B (NF-kB), p53-Mouse double minute 2 homolog (MDM2)
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complex and other oncoproteins and tumor suppressors [26]. It was shown that enhanced
proteasome activity, in turn, promotes the degradation of tumor suppressor proteins,
resulting in cancer cell survival and proliferation as well as the development of drug
resistance [27]. Noteworthy, when cancer cells acquire resistance to a specific anticancer
drug, they can become cross-resistant also to chemotherapeutics which affect different
molecular pathways [28]. It was shown that resistance to apoptosis induction, enhancement
of drug efflux, improvement of drug detoxification and modification of drug targets are
the mechanisms with a pivotal role in the acquisition of drug resistance capabilities [28].
Importantly, it was demonstrated that the increased proteasome activity detected in cancer
cells accelerates the turnover of IkBα (the NF-kB inhibitor), leading to an accumulation
of the pro-survival transcription factor NF-kB [29]. In addition, increased proteasome
activity in tumor cells can accelerate the degradation of the tumor suppressor Bcl-2-like
protein 4 (Bax), reducing the Bax/Bcl-2 ratio [30]. Another mechanism that leads to the
MDR phenotype is represented by an increase of the drug efflux, which is mediated by
ATP-binding cassette (ABC) transporters, including P-gp [31]. Interestingly, it was shown
that proteasome inhibitors successfully reversed the resistance to anticancer drugs in tumor
cells by decreasing P-gp levels [32].
2. Anticancer Effects of Phytochemicals Used Alone and in Combination with
Anticancer Drugs
Phytochemicals can be found in grains, vegetables, fruits and several foods [33]. Many
phytochemicals, like genistein and resveratrol, were combined with different antitumor
drugs for their synergistic anticancer effects against various forms of cancer [33]. Synergy
effect is broadly defined as the interaction or cooperation of two or more substances to
produce a combined effect greater than the sum of their individual effects [34]. Combina-
tional treatment with phytochemicals and anticancer drugs can suppress cancer recurrence
and reduce the resistance of tumor cells to chemotherapeutic agents [35]. Interestingly,
green beet and red beetroot have been described as vegetables rich in phytochemicals with
anticancer effects, like vitexin-2-O-xyloside, apigenin, betacyanins, betaxanthins, which
possess antitumor properties against colon, liver and bladder cancers [36]. These phyto-
chemicals are able to downregulate pro-survival genes BIRC5, catenin beta-1 (CTNNB1),
HIF1A, VEGFA and to inhibit the multidrug resistance mechanisms of tumor cells [36].
Phytochemicals extracted from green beet and red beet target several proteins, which
have been identified either as tumor suppressors, like Bax, FS-7-associated surface antigen
(Fas), p53, Bcl-2-associated agonist of cell death (Bad), TRAIL, or as oncoproteins, like
Bcl-2, Cyclooxygenase-2 (COX-2), Survivin, β-catenin, HIF1α, VEGF [36]. Importantly, the
chemopreventive and antitumor properties of several other phytochemicals, like curcumin,
resveratrol, sulforaphane and piperine have been demonstrated. The chemopreventive
action of curcumin and its synergistic effects, when combined with other phytochemicals
(like quercetin) and antitumor drugs (like tamoxifen and 5-fluorouracil (5-FU)) against
several cancers, have already been described [37]. Curcumin can reverse the drug resistance
to doxorubicin (DOX) or paclitaxel by directly inhibiting the expression of P-gp in cancer
cells [38,39]. Resveratrol is also able to reverse drug resistance in cancer cells by directly
affecting the efflux pumps. Importantly, co-administration of DOX with resveratrol led to
the reversal of drug resistance in various cancer cell lines, as a result of the downregula-
tion of Multidrug resistance-associated protein 1 (MRP1) and the reduced expression of
P-gp [40]. Interestingly, it was shown that sulforaphane re-sensitized Barrett esophageal
adenocarcinoma cells to the effects of the drug paclitaxel [41]. Importantly, piperine has
been extensively used to enhance the oral bioavailability of various drugs as it significantly
inhibits the expression of Cytochrome P450 (CYP3A4) and P-gp [42]. Bioavailability of
anticancer drugs enhanced by piperine includes docetaxel, etoposide and 5-FU [43–45].
In the following sections, we describe the antitumor properties and biological effects of
several combinations of phytochemicals and anticancer drugs against gastrointestinal
tumors: colon cancer, gastric cancer, liver cancer, pancreatic cancer.
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2.1. Colon Cancer
2.1.1. Antitumor Effects of Combinations of Curcumin with Anticancer Drugs in Colon Cancer
Extensive research has evidenced that curcumin, the main curcuminoid of turmeric
(C. longa), is able to decrease the resistance of cancer cells to several chemotherapeutic
agents, like gemcitabine, 5-FU, cisplatin and DOX in pancreas, colon, liver and gastric
tumors [46]. It has been shown that curcumin can sensitize colorectal cancer cells to
5-FU [47]. Interestingly, the effects of a combination of curcumin and bevacizumab were
studied in a xenograft model derived from the HT29 colorectal cancer cells [48]. Mice fed
with curcumin showed high bioavailability of the phytochemical and the combination
therapy induced remarkable anticancer effects [48]. In addition, curcumin effects were
assayed in two different human colon adenocarcinoma cell lines (HCT-116 and HT-29) and
the pancreatic cancer cell line Panc-28. Curcumin reduced the proliferation rate of tumor
cells, regulating NF-kB and Signal transducer and activator of transcription 3 (STAT3)
activity [49]. In addition, the combination of capecitabine and curcumin increased the
apoptotic rate of HCT-116 cells from 5% of cells to about 50% of cells [49]. Interestingly,
the combination of curcumin and irinotecan in LoVo cancer cells modulated the levels of
several therapy biomarkers: Glutathione S-transferase Mu 5 (GSTM5), Protein disulfide
isomerase (PDI), Peroxiredoxin 4 (PRDX4) [50]. Importantly, the combined use of irinotecan
and curcumin in an in vivo model of rat colorectal carcinogenesis remarkably reduced the
activity of P-gp (7-fold), inhibiting MDR mechanisms [51]. Furthermore, it was shown that
the combined therapy with curcumin and irinotecan reduced cancer growth and activated
the apoptotic process in HT-29 and LoVo colon cancer cells, through the modulation of
Binding Immunoglobulin Protein (BIP) and C/EBP Homologous Protein (CHOP) levels [52].
In addition, the authors demonstrated that the anticancer effects of this phytochemical
and drug combination were exerted through the modulation of ROS and the induction of
endoplasmic reticulum (ER) stress pathway [52]. Interestingly, a preclinical investigation
revealed that combination therapy with curcumin and dasatinib was highly effective in a
colon cancer model. The combination caused over 95% regression of intestinal adenomas in
Apc min/+ mice, which is linked to the reduced proliferation rate and increased apoptosis
induction [53]. Importantly, it was shown that curcumin is able to resensitize colon cancer
cells to the drug 5-FU in a 3D alginate tumor micro-environment, through the modulation
of the levels of MMP9, NF-kB and C-X-C Motif Chemokine Receptor 4 (CXCR4) [54].
Interestingly, the addition of 25 µM hexahydrocurcumin to a dose of 5 µM 5-FU exerts a
synergistic effect against the growth of HT-29 cells by significantly reducing cell viability
to a greater degree than monotherapy; the combination enhanced the growth inhibition of
cancer cells through the downregulation of COX-2 expression [55].
2.1.2. Antitumor Properties of Anticancer Drug and Phytochemical Combinations in
Colon Cancer
Importantly, it was demonstrated that resveratrol can reduce the resistance to 5-FU
of colon cancer cells through the reduction of slug and vimentin protein levels [56]. Inter-
estingly, in a rat model, the combination of 10 mg/kg resveratrol and 12 mg/kg cisplatin
treatments reduced the side effects of the drug [57]. In order to increase the anticancer
effects of resveratrol, Mohapatra et al. [58] studied the effects of the combined use of 15 µM
resveratrol and 0.5 µM 5-FU in colon cancer HCT-116 cells. This combination led to a
synergistic anticancer effect, exerted through the reduction of tumor cells proliferation
rate and migration capabilities, enhancement of DNA damages, induction of the apoptotic
process and block of the cell cycle in the S phase. Phosphorylation of both c-Jun N-terminal
kinase (JNK) and p38 mitogen-activated protein kinases (p38 MAPK) was increased by
this combination of resveratrol and 5-FU [58]. Interestingly, it was shown that a combi-
nation of 5-FU and EGCG reduced the growth of HCT116 and DLD1 colon cancer cells,
through the glucose-regulated protein 78 (GRP78)/NF-kB/miR-155-5p/MDR1 pathway
inhibition [59]. Importantly, it was shown that 5-FU and EGCG co-loaded nanoparticles
exhibited remarkable anti-tumor activity and pro-apoptotic efficacy in both in vitro and
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in vivo colon cancer models [60]. Interestingly, the combination of EGCG and sodium
butyrate induced G2/M arrest in RKO and HCT-116 colon cancer cells, and G1 arrest
in HT-2 cancer cell line, through the modulation of the levels of Histone deacetylase 1
(HDAC1) and DNA (cytosine-5)-methyltransferase 1 (DNMT1) [61].
Interestingly, the combination of thymoquinone and topotecan inhibited the proliferation
of colon cancer cells through caspases activation and induction of cell cycle arrest during the
S phase [62]. Furthermore, the authors indicated that the combination of this phytochemical
with the anticancer drug remarkably reduced the growth of tumor cells without involving
Bax, Bcl-2 and p53 [62]. In addition, the combination of DOX and thymoquinone reduced the
proliferation rate of HT-29 colon cancer cells [63]. Interestingly, several authors studied the
antiproliferative effects of thymoquinone in LoVo cancer cells resistant to the chemotherapeutic
agent irinotecan, showing that this natural molecule can regulate JNK and p38 pathways
affecting Extracellular signal-regulated kinases 1/2 (ERK1/2), Phosphoinositide 3-kinase
(PI3K) and is also able to induce the autophagic process [64,65].
Interestingly, Palko-Labuz A. et al. [66] demonstrated that the combination of baicalein
and DOX in colorectal cancer cells induced the activation of caspase 3 along with DNA
fragmentation, the downregulation of proliferating cell nuclear antigen (PCNA) and growth
inhibition. Importantly, 5-FU and ellagic acid remarkably inhibited the growth of colon
cancer cells SW480, HT-29 and Colo320DM. The synergism between these two molecules
was exerted through the activation of the apoptotic process in HT-29 cells, where the
authors described an increase of the Bax/Bcl-2 ratio, cleaved caspase 3 and cleaved Poly
ADP-ribosyl polymerase 1 (PARP1), and also loss of mitochondrial membrane potential [67].
Interestingly, the effects of the combination of ursolic acid and capecitabine were studied in
in vitro and in vivo models of colon cancer [68]. The combined treatment reduced tumor
volume and distant metastases in vivo. In addition, this combination of phytochemical
and anticancer drugs regulated several signaling pathways, modulating the levels of key
factors such as NF-kB, STAT3, β-catenin, Epidermal growth factor receptor (EGFR), p53,
p21, matrix metallopeptidase 9 (MMP-9), VEGF and intercellular adhesion molecule 1
(ICAM 1) [68]. Importantly, it was demonstrated that berberine, in combination with DOX,
5-FU, CPT or taxol, in in vitro models of colon, gastric and pancreatic cancer, induced the
intrinsic apoptosis, increased apoptosis inducing factor (AIF) levels, decreased Interleukin
6 (IL6) and STAT3 levels and inhibited Janus kinase (JAK)/STAT and MAPK/ERK pro-
survival pathways [69–73]. Importantly, it was shown that the combination of cetuximab
and tectochrysin in HCT116 and SW480 tumor cells decreased the expression of p-EGFR
and COX-2 and, in addition, inhibited NF-kB and Activator protein-1 (AP-1), inducing
the death of tumor cells [74]. Interestingly, the effect of a combination of terpinen-4-ol
and cetuximab was analyzed in Kirsten rat sarcoma virus (KRAS) mutated HCT116 cells
and also in an in vivo mouse model, showing that this combined treatment remarkably
reduced tumor growth (80–90%) and also tumor volume (62%) [75]. Importantly, casticin
has been demonstrated to potentiate Tumor necrosis factor (TNF)-related apoptosis in colon
cancer cells through downregulation of survival proteins such as Bcl-2, B-cell lymphoma
extra large (Bcl-xL), survivin, X-linked inhibitor of apoptosis protein (XIAP) and cellular
FLICE-like inhibitory protein (cFLIP) and upregulation of DR5 [76]. Interestingly, it was
shown that the use of a combination of β-Sesquiphellandrene and thalidomide in HCT116
cells decreased the levels of anti-apoptotic proteins cFLIP, Bcl-xL, Bcl-2, cellular inhibitor
of apoptosis protein 1 (c-IAP1) and survivin [77]. Furthermore, the antitumor effects of
the phytochemical β-caryophyllene and the anticancer drug paclitaxel were studied in
DLD-1 colorectal cancer cells, showing a synergistic inhibition of proliferation rate of tumor
cells and an accumulation of the chemotherapeutic agent inside the cancer cells [78]. In
addition, β-caryophyllene and β-caryophyllene oxide chemosensitized Caco-2 tumor cells
to the effects of DOX [79]. The authors indicated that these phytochemicals inhibited
the MDR mechanisms of the tumor cells, enhancing DOX antiproliferative effects [79].
Interestingly, it was shown that Mistletoe extract, in combination with DOX, paclitaxel,
cisplatin, doxifluridine or cyclohexamide, in experimental models of colon, liver, pancreatic
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and gastric cancer induced the apoptotic process and an increase of ROS levels [80–82].
Importantly, it was shown that a combination of irinotecan and panaxadiol decreased
HCT116 proliferation rate through the activation of apoptosis and an increase of cleaved
caspase 9 and caspase 3 levels [83].
Interestingly, it was shown that Vitamin D (which can be found in several foods, like
cheese, meat, eggs and fish) exerts chemopreventive effects in several solid tumors, in par-
ticular in colorectal cancer [84]. In vitro studies indicated that vitamin D is able to reduce
the proliferation of colorectal cancer cells through the induction of the apoptotic process,
the block of the cell cycle in G1 phase and the angiogenesis inhibition [85–88]. Noteworthy,
the inhibitory effects of 25-hydroxy vitamin D3 (1,25(OH)2D3) on cell proliferation and
apoptosis are underlined by the findings that this molecule promotes sensitivity to the
chemotherapeutic agent 5-FU by down-regulating the expression of the anti-apoptotic
protein survivin and of thymidylate synthase, a key enzyme in the biosynthethic pathway
of DNA [84]. Furthermore, studies on different colon carcinoma cell lines showed that
1,25(OH)2D3 may promote apoptosis by the up-regulation of the pro-apoptotic protein
Bcl-2 homologous antagonist/killer 1 (BAK1) and the down-regulation of the nuclear
anti-apoptotic protein Bcl-2-associated athanogene 1 (BAG1) [88]. Interestingly, it was
demonstrated that treatment of Caco-2 colon cancer cells with 1,25(OH)2D3 induced an
increase in the expression of p21, p27, E-cadherin, and other adhesion proteins ((Zonula
occludens-1 (ZO-1), Zonula occludens-2 (ZO-2), and vinculin)) and promoted the translo-
cation of β-catenin and ZO-1 from the nucleus to the plasma membrane [89]. Regarding
in vivo experiments, Meeker et al. [90], by using a mouse model of bacteria-driven colitis
and colon cancer, when infected with Helicobacter bilis (H. bilis), showed that mice fed
high vitamin D diet had a significantly lower incidence of cancer compared with mice
fed maintenance diet. These findings further suggest that increased dietary vitamin D is
beneficial in preventing inflammation-associated colon cancer through the suppression
of inflammatory responses during the initiation of neoplasia or early-stage carcinogene-
sis [84]. The molecular pathways and molecular targets modulated by the combinations of
phytochemicals and anticancer drugs in colon cancer models are reported in Table 1.
Table 1. Colon cancer targets.
Phytochemical-Drug
Combinations Molecular Mechanisms Molecular Targets References
Curcumin+5-FU Resensitizing cancer cells to 5-FU effects EMT markers [47]
Curcumin+Bevacizumab Proliferation inhibition Ki-67 [48]
Curcumin+Capecitabine Apoptosis induction NF-kB; STAT3 [49]
Proliferation inhibition
Curcumin+Irinotecan Apoptosis induction GSTM5; PDI; PRDX4 [50]
Resensitizing cancer cells to irinotecan effects
Curcumin+Irinotecan ER stress induction BIP; CHOP [52]
Apoptosis induction
ROS level increase
Curcumin+Dasatinib Proliferation inhibition COX-2; Bcl-xL; EGFR [53]
Apoptosis induction
Curcumin+5-FU Resensitizing cancer cells to 5-FU effects NF-kB; CXCR4; MMP9 [54]
Hexahydrocurcumin+5-FU Proliferation inhibition COX-2 [55]
Resveratrol+5-FU Apoptosis induction EMT markers [56]
Resensitizing cancer cells to 5-FU effects
Resveratrol+5-FU Proliferation inhibition JNK; p38 MAPK; [58]
Reduction of migration capacity Caspase 3
Induction of DNA damage
Apoptosis induction
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Table 1. Cont.
Phytochemical-Drug
Combinations Molecular Mechanisms Molecular Targets References
EGCG+5-FU Proliferation inhibition GRP78; NF-kB; [59]
Resensitizing cancer cells to 5-FU effects miR-155-p; MDR1
EGCG+5-FU Resensitizing cancer cells to 5-FU effects Caspase 3 [60]
Proliferation inhibition
EGCG+Sodium butyrate G2/M phase cell cycle arrest HDAC1; DNMT1; p53; [61]
Apoptosis induction p21; Survivin
Thymoquinone+Topotecan Apoptosis induction Caspase 3 [62]
S phase cell cycle arrest
Proliferation inhibition
Thymoquinone+DOX Proliferation inhibition Caspase 3 [63]
Thymoquinone+Irinotecan Autophagic cell death induction JNK; p38 MAPK; PI3K; [64,65]
Inhibition of metastasis process ERK 1/2; NF-kB
Baicalein+DOX Apoptosis induction Caspase 3; PCNA [66]
DNA damage induction
Ellagic acid+5-FU Apoptosis induction Bax; Bcl-2; Caspase 3; [67]
Proliferation inhibition PARP1
Ursolic acid+Capecitabine Inhibition of metastasis process NF-kB; STAT3; EGFR; [68]
Reduction of tumor volume β-catenin; p53; p21;
Inhibition of pro-survival mechanisms MMP-9; VEGF; ICAM-1
Berberine+DOX Apoptosis induction AIF; IL-6; STAT3; JAK; [69,71,73]
Berberine+5-FU Proliferation inhibition MAPK; ERK
Berberine+Taxol Inhibition of pro-survival mechanisms
Tectochrysin+Cetuximab Proliferation inhibition p-EGFR; COX-2; AP-1; [74]
NF-kB
Terpinen-4-ol+Cetuximab Reduction of tumor volume KRAS [75]
Casticin+TNF Apoptosis induction Bcl-2; Bcl-xL; Survivin; [76]
XIAP; cFLIP; DR5
β-sesquiphellandrene+Thalidomide Apoptosis induction cFLIP; Bcl-xL; Bcl-2; [77]
c-IAP1; Survivin
β-caryophyllene+Paclitaxel Resensitizing cancer cells to paclitaxel effects P-gp [78]
β-caryophyllene+DOX Resensitizing cancer cells to DOX effects P-gp [79]
Mistletoe extract+Gemcitabine Apoptosis induction Caspase 3 [82]
Panaxadiol+Irinotecan Apoptosis induction Caspase 9; Caspase 3 [83]
2.2. Gastric Cancer
Noteworthy, it has been shown in human gastric cancer cells that the use of RNA
interference techniques targeting both the poly-ubiquitin genes Ubiquitin B (UBB) and
Ubiquitin C (UBC) can remarkably decrease the proliferation rate of 23132/87 primary
gastric cancer cell line, through the increase of pro-apoptotic Fas protein levels, the decrease
of ubiquitinated H2A histone and oncoprotein β-catenin levels, the activation of caspase 3
and the induction of the apoptotic process [91]. Interestingly, it was shown that the
synergistic cytotoxic effect of the combination between curcumin and oxaliplatin or 5-FU
in both in vitro and in vivo gastric cancer models was exerted through the activation of
the mitochondria-dependent apoptosis, where the regulation upon caspase 9 and 3, Bcl-2,
ERK1/2 as well as Wingless-related integration site (WNT)/β-catenin played a role [92].
Importantly, by activating Phosphatase and tensin homolog (PTEN), resveratrol inhibited
the activity of the Rac-alpha serine/threonine-protein kinase (AKT) signaling pathway,
re-sensitizing gastric cancer cells to DOX while reducing the metastasis capacity of cancer
Appl. Sci. 2021, 11, 10077 8 of 21
cells [93]. Interestingly, the amelioration of P-gp, as well as the inhibition towards the
secretion of VEGF by EGCG contributed to the reversal of drug resistance against 5-FU
in gastric cancer cell line SGC-7904/FU, exhibiting enhanced inhibitory effects both in
in vitro and in vivo conditions [94]. In addition, the treatment of the gastric cancer cell
line BGC-823 with the combination of EGCG and docetaxel showed synergistic inhibition
of tumor volume in xenograft mouse models [95]. Interestingly, other than the effects on
cancer growth inhibition, berberine can also overcome drug-resistance in combination
with the use of clinical chemotherapeutic drugs. In fact, berberine increased the effect
of heat-shock protein 90 (Hsp90) inhibitor in colon cancer cells and showed synergism
with 5-FU against gastric cancer cells [73,74]. Importantly, mithramycin A associated
with bevacizumab produced synergistic tumor suppression, modulating the expression of
Specificity protein 1 (Sp1) and its downstream target genes, thus strongly reducing gastric
cancer angiogenesis and metastasis [96]. Regarding the antitumor properties of vitamin D,
Pan et al. [97] have shown that 1,25(OH)2D3 may promote apoptosis in the HCG-27 gastric
cancer cell line. This effect appears to be the result of the up-regulation of PTEN, the tumor
suppressor gene that negatively regulates the anti-apoptotic activity of Akt. The molecular
pathways and molecular targets modulated by the combinations of phytochemicals and
anticancer drugs in gastric cancer models are reported in Table 2.
Table 2. Gastric cancer targets.
Phytochemical-Drug
Combinations Molecular Mechanisms Molecular Targets References
Berberine+5-FU Proliferation inhibition Survivin; STAT3 [72]
Curcumin+Oxaliplatin Apoptosis induction Caspase 9; Wnt/β-catenin [92]
Curcumin+5-FU Inhibition of pro-survival mechanisms Caspase 3; Bcl-2; ERK1/2
Resveratrol+DOX Resensitizing cancer cells to DOX effects PTEN; Akt [93]
Reduction of metastasis capacity
EGCG+5-FU Proliferation inhibition P-gp; VEGF; MDR1 [94]
Resensitizing cancer cells to 5-FU effects
EGCG+Docetaxel Reduction of tumor volume Ki-67; VEGF [95]
Mithramycin A+Bevacizumab Angiogenesis inhibition Sp1; VEGF [96]
Reduction of metastasis capacity
2.3. Liver Cancer
The antiproliferative effects of EGCG were studied in liver cancer both in vitro and
in vivo. EGCG in combination with sorafenib inhibited cell growth both in liver cancer cell
lines and xenografted mice, specifically targeting the glycolytic pathway [98]. Interestingly,
it was shown that the combined treatments of DOX + EGCG and DOX + Epicatechin-3-
gallate (ECG) exerted significant cytotoxic effects in both BEL-7404 and BEL-7404/DOX
hepatocellular carcinoma cells, through the reduction of MDR1 and HIF-1α levels [99].
Furthermore, the combination of DOX and these phytochemicals reduced tumor volume in
in vivo models [99]. Interestingly, a combination of EGCG and 5-FU increased the antitumor
effects of 5-FU in Hep3B cells, through the modulation of Akt, COX-2, Prostaglandin E2
(PGE2) levels [100]. Moreover, it was shown that the combined treatment with Y6 (EGCG-
derivative) and DOX in liver cancer cells BEL-7404/DOX reduced P-gp activity, leading to
a 10 fold decrease of DOX IC50 value, and remarkably induced the apoptotic process [101].
Importantly, it was shown that the combination of bevacizumab and curcumin in an
in vivo model of liver cancer was able to inhibit VEGF/Vascular endothelial growth factor
receptor (VEGFR)/K-ras signaling pathways [102]. Interestingly, the curcumin-derived
compound EF24 enhanced the anticancer effects of sorafenib by inhibiting MDR mecha-
nisms through the modulation of Von Hippel-Lindau (VHL) and HIF-1α, in liver cancer
in vitro and in vivo models [103]. Interestingly, genistein shows synergistic behavior with
well-known anticancer drugs, such as adriamycin, docetaxel and tamoxifen, suggesting
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a potential role in combinational anticancer therapy [104]. Importantly, it was shown
that the combination of TRAIL and genistein was able to increase the apoptosis induction
rate in Hep3B liver cancer cells [105]. In addition, it was demonstrated that the use of
arsenic trioxide (ATO) and genistein led to the reduction of the proliferation rate and to the
induction of the apoptotic process in liver cancer cells, exerted through the inhibition of
Akt and NF-kB [106]. Moreover, the combination of this phytochemical (50 µg genistein/g)
with ATO reduced both tumor growth and angiogenesis in a xenograft mouse model [106].
Importantly, Wu S. et al. [107] studied the in vivo anticancer effects of a combination of
resveratrol and 5-FU against Hepatoma 22 transplanted Balb/c mice xenografts, demonstrat-
ing the S phase arrest of Hepatoma 22 cells and the resveratrol-mediated enhancement of
the anti-tumor effect of 5-FU in this xenograft model [107]. Regarding the phytochemicals of
cruciferous vegetables, the anticancer effects of indole-3 carbinol were studied in combination
with sorafenib in liver cancer cells HepG2 and Huh-7, showing that this association potenti-
ated apoptosis and decreased angiogenesis process, especially in HepG2 cells, through the
modulation of the levels of EMT markers and NADPH oxidase 1 (NOX1) [108]. In addition, in
hepatocellular carcinoma model, an isocorydine derivative decreased cancer cell proliferation
and induced apoptosis, in association with sorafenib, through the modulation of the levels of
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) [109]. Importantly, cytotoxic-
ity of DOX to HepG2 liver cancer cells was increased in combination with naringenin [110].
This study attributes the synergistic effect of this association to its ability to modulate the activ-
ity of MRPs, promote apoptosis and inhibit angiogenesis [110]. Interestingly, Shi R. et al. [111]
demonstrated the in vitro and in vivo anticancer effects of a combination of cisplatin and lute-
olin against both liver cancer cell lines HepG2 and Hep3B and colorectal cancer cells HT29 and
HCT116 and also HCT116-BALB/c nude mice xenografts. The antiproliferative effects were
mediated by stabilization of tumor suppressor p53, increased JNK activation and induction of
apoptosis [111]. Importantly, Xu Y et al. [112] demonstrated the antiproliferative activity of a
combination of apigenin and paclitaxel against Hep3B liver cancer cells, which was exerted
through inhibition of Superoxide dismutase (SOD) activity, ROS-induced activation of caspase
2 and MMPs, increased cleavage of caspase 3 and PARP1 [112]. Regarding the phytochemical
quercetin, a selective antiproliferative-boosting effect of this flavonoid on DOX was observed
in hepatoma cells SMMC7721 with no significant cytotoxicity in normal liver cells L02 [113]. In
particular, the addition of 20 µM quercetin facilitated DOX accumulation in SMMC7721 cells
and subsequently augmented cell apoptosis [113]. Interestingly, L-canavanine, a phytochemi-
cal found in several plants of the Fabaceae family, potentiated the cytotoxicity of vinblastine
and paclitaxel in hepatocarcinoma cells [114]. Importantly, Zhang and collaborators examined
Momordica charantia L. lectin effects, used at the dose of 0.5 mg/Kg combined with sorafenib (at
the dose of 30 mg/kg) in xenografted mice of HepG2 cells and in liver cancer cell lines. These
authors documented that M. charantia L. lectin enhanced the lethal effects of sorafenib both in
cell and animal models, decreasing cancer cell viability by more than 3 fold and tumor weight
by about 50% [115]. The molecular pathways and molecular targets modulated by the combi-
nations of phytochemicals and anticancer drugs in liver cancer models are reported in Table 3.
Table 3. Liver cancer targets.
Phytochemical-Drug
Combinations Molecular Mechanisms Molecular Targets References
EGCG+Sorafenib Proliferation inhibition Phosphofructokinase [98]
Inhibition of glycolytic pathway
EGCG+DOX Proliferation inhibition P-gp; MDR1; HIF-1α [99]
ECG+DOX Reduction of tumor volume
Resensitizing cancer cells to DOX effects
EGCG+5-FU Resensitizing cancer cells to 5-FU effects COX-2; PGE2; Akt [100]
Y6 (EGCG derivative)+DOX Resensitizing cancer cells to DOX effects P-gp [101]
Apoptosis induction
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Table 3. Cont.
Phytochemical-Drug
Combinations Molecular Mechanisms Molecular Targets References
Curcumin+Bevacizumab Angiogenesis inhibition VEGF; VEGFR; KRAS [102]
Reduction of tumor volume
EF24 (Curcumin
derivative)+Sorafenib Resensitizing cancer cells to sorafenib effects VHL; HIF-1α [103]
Proliferation inhibition
Genistein+TRAIL Proliferation inhibition MAPK; Caspase 8 [105]
Apoptosis induction
Genistein+ATO Proliferation inhibition Akt; NF-kB [106]
Apoptosis induction
Angiogenesis inhibition
Resveratrol+5-FU S phase cell cycle arrest Ki-67 [107]
Resensitizing cancer cells to 5-FU effects
Indole-3-carbinol+Sorafenib Apoptosis induction EMT markers; NOX1 [108]
Angiogenesis inhibition
Isocorydine
derivative+Sorafenib Apoptosis induction IGF2BP3 [109]
Proliferation inhibition
Naringenin+DOX Apoptosis induction MRPs [110]
Angiogenesis inhibition
Luteolin+Cisplatin Apoptosis induction p53; JNK [111]
Proliferation inhibition
Apigenin+Paclitaxel Proliferation inhibition SOD; Caspase 2; MMPs; [112]
Caspase 3; PARP1
Quercetin+DOX Resensitizing cancer cells to DOX effects p53; Bcl-xL [113]
L-canavanine+Vinblastine Proliferation inhibition P-gp [114]
L-canavanine+Paclitaxel
Lectin+Sorafenib Proliferation inhibition Ki-67 [115]
Reduction of tumor volume
2.4. Pancreatic Cancer
Genistein enhances the efficacy of chemotherapy mainly by inhibiting survival signals
and/or enhancing apoptotic signals. It was reported that genistein pretreatment inactivated
NF-kB and contributed to growth inhibition and apoptosis induced by cisplatin, docetaxel,
DOX or gemcitabine in various tumor cells including prostate, breast, lung, pancreatic and
ovarian cancers [116,117]. Interestingly, genistein has been investigated as a sensitizer to
gemcitabine and erlotinib in cancer cell lines and in patients with pancreatic cancer [24]. In
addition, genistein was tested for its synergistic combination with gemcitabine in two murine
xenografts of human pancreatic carcinoma cells (COLO357 and L3.6pl) and this treatment
led to antiproliferative effects and reduction of tumor volume [117]. Furthermore, genistein
restored the sensitivity to oxaliplatin in gemcitabine-resistant pancreatic cancer cells in both
in vitro and in vivo models [118]. Importantly, several flavonoids including genistein and
quercetin were found to downregulate MRP1 in resistant human tumor cell lines, such as
pancreatic adenocarcinoma cells Panc-1, suggesting their MDR reversal potential [119].
Regarding the use of TRAIL in antitumor therapies, the combination of EGCG and
TRAIL significantly diminished the proliferation of human pancreatic cancer cell line
MIA PaCa-2 and increased both cleavage of procaspase-2 and apoptosis induction [120].
Importantly, the anticancer and pro-apoptotic effects of a combination of EGCG and
thymoquinone in pancreatic PANC-1 cancer cell line [121] and a combination of EGCG and
celecoxib in pancreatic cancer cell line Colo357 [122] have been described. Interestingly,
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the sensitization of pancreatic cancer cells for TRAIL treatment in association with benzyl
isothiocyanate (extracted from cruciferous vegetables) has been demonstrated [123].
Importantly, Harikumar KB et al. [124] described the anticancer effects of a combination
of resveratrol and gemcitabine against both pancreatic cancer cell lines AsPC-1, MIA PaCa-2,
Panc-1, Panc-28 and also MIA-PaCa-2 cells-orthotopic mice model xenografts. The authors
evidenced the downregulation of NF-kB, Bcl-2, Bcl-xL, COX-2, cyclin D1, MMP-9, VEGF,
proliferation marker Ki-67, the micro-vessel density marker Clusters of differentiation 31
(CD31) and ICAM-1 [124]. Interestingly, Kallifatidis G. et al. [125] described the anticancer
effects of a combination of sulforaphane and gemcitabine against both pancreatic CSCs and
MIA-PaCa2 cells-xenografted BALB/c nude mice. The authors described a decrease of NF-kB
activity, the downregulation of Notch homolog 1 translocation-associated (NOTCH-1) and
Transcription factor p65, inhibition of aldehyde dehydrogenase 1 (ALDH1) activity, decreased
proliferation of the subpopulation of CSCs, reduction of the growth of xenografts and
inhibition of the relapse of drug-treated cancer cells in the mouse model [125]. Furthermore,
also the phytochemical cucurbitacin B potentiated the inhibitory effects of gemcitabine in
pancreatic tumors, through the modulation of the levels of Bcl-xL, Bcl-2, JAK and cellular-
Myelocytomatosis oncogene product (c-myc) [126].
Regarding the use of the DNA and RNA polymerase inhibitor mithramycin A, this
compound was used in combination with the phytochemical betulinic acid and the anticancer
drug gemcitabine in xenograft mouse models of human pancreatic cancer, where the authors
observed a decrease of Sp1 and VEGF levels [127]. Moreover, it was shown that the combina-
tion of tolfenamic acid and mithramycin A exerted remarkable antitumor effects in an in vivo
pancreatic cancer model through the decrease of Sp1 protein levels [128]. Interestingly, in an
orthotopic pancreatic cancer mouse model obtained with PANC-1 cells, B-carboline in combi-
nation with gemcitabine reduced tumor burden and metastatic potential development [129].
Importantly, it was shown that red beetroot (Beta vulgaris) extract together with DOX induced
synergistic antiproliferative effects against pancreatic PaCa-2 tumor cells [130]. The molecular
pathways and molecular targets modulated by the combinations of phytochemicals and
anticancer drugs in pancreatic cancer models are reported in Table 4.
Table 4. Pancreatic cancer targets.
Phytochemical-Drug
Combinations Molecular Mechanisms Molecular Targets References
Genistein+Erlotinib Resensitizing cancer cells to erlotinib effects Ubiquitin; Proteasome [24]
Genistein+Gemcitabine Proliferation inhibition NF-kB [116,117]
Reduction of tumor volume
Genistein+Oxaliplatin Resensitizing cancer cells to oxaliplatin effects NF-kB; Ki-67 [118]
EGCG+TRAIL Apoptosis induction Caspase 2; Caspase 3 [120]
Proliferation inhibition
EGCG+Celecoxib Proliferation inhibition IL-1 [122]
Benzyl isothiocyanate+TRAIL Apoptosis induction Caspase 8; Caspase 3 [123]
Resveratrol+Gemcitabine Proliferation inhibition NF-kB; Bcl-2; Bcl-xL; [124]
Angiogenesis inhibition COX-2; Cyclin D1; VEGF;
Reduction of tumor volume MMP-9; Ki-67; CD31
Sulforaphane+Gemcitabine Proliferation inhibition NF-kB; NOTCH-1; p65; [125]
Reduction of tumor volume ALDH1
Inhibition of CSCs growth
Cucurbitacin B+Gemcitabine Resensitizing cancer cells to gemcitabine effects Bcl-xL; Bcl-2; JAK; c-myc [126]
Betulinic acid+ Mithramycin A Proliferation inhibition Sp1; VEGF [127]
Angiogenesis inhibition
Reduction of metastasis capacity
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Table 4. Cont.
Phytochemical-Drug
Combinations Molecular Mechanisms Molecular Targets References
Tolfenamic
acid+Mithramycin A Reduction of tumor volume Sp1 [128]
B-Carboline+Gemcitabine Reduction of tumor volume Ki-67 [129]
Reduction of metastasis capacity
Red beetroot extract+DOX Proliferation inhibition Caspase 3 [130]
3. Phytochemicals and Anticancer Drugs Targeting Cancer Stem Cells
CSCs represent a sub-population of tumor cells able to self-renew and to originate
the different types of tumor cells which can be found in the tumor mass; specific gene
mutations are required to generate CSCs from the normal stem cells [131]. The in vitro and
in vivo anticancer effects of phytochemicals targeting CSCs have been described, indicating
the inhibition of their MDR mechanisms and self-renewal capabilities [132]. Interestingly, it
has been shown that the growth of CSCs can be inhibited by both phytochemicals (EGCG,
sulforaphane) and whole natural extracts, like Sasa quelpaertensis [132]. Importantly, many
phytochemicals target the Wnt (β-catenin/T cell factor-lymphoid enhancer factor (TCF-
LEF)) pathway, inhibiting this pro-survival mechanism [132]. Conventional chemotherapy
targets the bulk of proliferating cancer cells; as it was described for the effects of paclitaxel
against several solid tumors and imatinib against chronic myelogenous leukemia; however,
CSCs are resistant to these anticancer drugs [133]. An efficient antitumor therapy should
acknowledge CSCs plasticity and their complete elimination. Many compounds (natural,
natural-derived, synthetic) have been described as CSC-targeting and these compounds are
able to target only CSCs and not normal stem cells [134–136]. Regarding CSCs targeting,
Chan MM et al. [137] described the anticancer effects of several dietary phytochemicals
and some repurposed drugs (Figure 2).
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Phytochemicals obtained from the diet and repurposed drugs ar pleiotropic, i. .,
they can target many hallmarks of cancer nd molecular pathways. Interestingly, it was
shown that a combination of 5-FU and curcumin decreased the growth of colorectal CSCs,
evidenced by a decrease of EMT marker protein levels and through co-culture assays [139].
Importantly, Chen et al. [140] showed that EGCG inhibited the growth of spheroids ob-
tained from colon cancer CSCs, through inhibition of the Wnt pathway, as indicated by
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a decrease in β -catenin protein levels. Furthermore, Montales et al. [141] reported that
metformin and genistein targeted colon CSC spheroid formation and proliferation and
their combination increased the effectiveness of 5-FU. Interestingly, Huang et al. [142]
reported that genistein inhibited spheroids growth and stemness characteristics, through
downregulation of Octamer-binding transcription factor 4 (Oct4) and Homeobox protein
NANOG (Nanog) gene expression, and reduced tumor volume of xenografts derived from
gastric cancer CSCs. Importantly, it was shown that in hepatocellular carcinoma CSCs,
curcumin inhibited Sp1, invasion, EMT process and decreased tumor size in a xenograft
model [143]. Regarding the CSCs of pancreatic tumors, Shankar et al. [144] indicated that
resveratrol was able to inhibit the growth of pancreatic CSCs through the activation of the
apoptotic process, the reduction of expression of Oct4 and Nanog and the interference with
the EMT process. Interestingly, Ning et al. [145] showed that a combination of curcumin
and metformin inhibited pancreatic CSCs spheroids growth.
4. Drugs and Phytochemicals against Gastrointestinal Tumors in Clinical Practice
Several combinations of anticancer drugs and phytochemicals have reached Phase
I, II or III of clinical trials concerning gastrointestinal tumors. Interestingly, the phyto-
chemical curcumin has been used in combination with gemcitabine and celecoxib in a
phase III clinical trial against colon neoplasm, in combination with irinotecan in a phase I
clinical trial against metastatic colorectal cancer and also with capecitabine against rectal
cancer in a phase II clinical trial [33]. Importantly, several case–control studies and cohort
studies analyzed the relationship between vitamin D intake and the risk of colorectal can-
cer [146,147]. These studies indicated that the relationship between the serum 25(OH)D3
level and colorectal cancer risk generally shows an inverse association [148–152]. Inter-
estingly, it was demonstrated that daily administration of resveratrol (0.5–1 g/day, for
8 days) before surgery in patients with colorectal cancer could reduce the rate of tumor
cell proliferation [153]. Importantly, it was shown that the phytochemicals extracted from
green tea, in combination with sulindac, celecoxib, leptomycin B, DOX or cisplatin, in colon
and esophageal cancer clinical trials reduced SOD and COX2 activity and showed antipro-
liferative effects [154]. Interestingly, a combination of mistletoe extract and commonly used
chemotherapeutic drugs (including DOX), can remarkably induce the apoptotic process
in tumor cells in several clinical trials [81]. Furthermore, the combination therapy based
on the mistletoe extract and doxofluridine significantly increased the health status and
eosinophil and leukocyte counts in gastric cancer patients when compared to untreated
patients [81]. Importantly, the therapy based on SRT501 (a resveratrol oral formulation) at
the dose of 5 g daily for two weeks induced the cleavage of caspase 3 and the induction
of the apoptotic process in malignant hepatic tissues of colon cancer patients with liver
metastases [155]. Interestingly, it was shown that curcumin, in combination with several
anticancer drugs and phytochemicals, in clinical trials of pancreatic and colon cancer, in-
creased the levels of tumor suppressors Bax, Bak, p53 upregulated modulator of apoptosis
(PUMA) and decreased the levels of oncoproteins Bcl-2, Bcl-xL, Nuclear factor erythroid
2-related factor 2 (Nrf2), VEGF, mechanistic target of rapamycin (mTOR), NF-kB, COX-2,
pSTAT3, Matrix metallopeptidase 2 (MMP2) and MMP9 [156–158]. Regarding the use of the
anticancer drug gemcitabine in combination with phytochemicals, in a phase I/II clinical
trial in Japan, 21 patients affected by pancreatic cancer received a therapy based on the
combination of gemcitabine and curcumin (8 g/day), noteworthy, no patient had a partial
response and five had a stable disease [159]. Importantly, in this phase II clinical study,
the curcumin plasma levels of the treated patients ranged from 29 to 412 ng/mL [159].
Interestingly, a therapy based on the combination of gemcitabine, curcumin and Celebrex
was used in a phase III clinical trial against pancreatic and colon tumors [24]. Importantly,
the combined effect of gemcitabine and curcumin against pancreatic cancer was evaluated
in a phase II clinical trial [160]. Pancreatic cancer patients (n = 17) were supplemented 8 g of
curcumin daily for 4 weeks, in combination with gemcitabine; unluckily, this therapy was
not able to significantly improve the clinical conditions of the patients [160]. Interestingly,
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genistein has been utilized also in combination with gemcitabine and erlotinib against
metastatic pancreatic cancer in a recent Phase II clinical trial and the authors evidenced that
the antitumor effect was exerted by the modulation of p-Akt and NF-kB levels, mediated
by the combination of the phytochemical and the anticancer drugs [33].
5. Conclusions and Future Perspectives
Dietary phytochemicals have low or no toxicity, can be found in commonly consumed
foods and have also shown potential as adjuvants in chemotherapy strategies and for chemo-
prevention [161,162]. Since initiation (chemoprevention) and growth (cancer chemotherapy)
share common molecular pathways and mechanisms, they were applied to anticancer ther-
apy, but the use of phytochemicals in antitumor therapies present some limitations, including
poor bioavailability of phytochemicals, improper systemic delivery and patient’s different
genetic characteristics [33]. It is important to note that an efficient therapeutic approach is
based on the accumulation of drugs and phytochemicals in the cancer site; in addition, the
low bioavailability of the anticancer compounds may hinder their sufficient accumulation.
For most natural molecules obtained from the diet, the hydrophobicity and the short half-life
can lead to low bioavailability, reducing the efficiency of the therapies [163]. Noteworthy,
it should be taken into account that many natural compounds may modulate the activity
of CYP450, which is involved in the metabolism of several drugs and compounds [164].
The regulation of CYP450 activity would lead to alterations of the pharmacokinetic char-
acteristics of phytochemicals and chemotherapeutics used in combination. In addition,
the influence on the drug-metabolizing enzymes would lead to a further reduction of the
phytochemical and drug bioavailability [164]. In order to solve this problem, biopolymeric
nanoparticles and micelles have been used for obtaining an efficient co-delivery of drugs and
phytochemicals [165]. In order to obtain the precise release of drugs specifically targeting the
tumor sites, several strategies have been developed: from hydrogels to polymeric prodrugs
and micelles able to self-assemble, with promising perspectives both in in vitro and in vivo
cancer models [163]. Importantly, being versatile carriers for many chemotherapeutics and
natural molecules, liposomes have been used to perform the co-delivery of phytochemicals
and repurposed drugs in combination with anti-tumor therapeutics [163]. Interestingly,
inorganic materials, like mesoporous silica nanoparticles, have been used as carriers for the
delivery of conventional antitumor drugs, repurposed drugs and natural compounds [166].
In conclusion, the increased knowledge of biomarkers and molecular pathways modulated
by the phytochemical and anticancer drug combinations in tumor cells and xenograft cancer
models, together with the use of innovative molecular biology techniques, will remarkably
improve the efficacy of these therapeutic strategies against gastrointestinal tumors and also
other solid tumors in future clinical applications.
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